Aeolus Pharmaceuticals Competitors

Akorn (OTCMKTS:AKRXQ) and Aeolus Pharmaceuticals (OTCMKTS:AOLS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

Earnings & Valuation

This table compares Akorn and Aeolus Pharmaceuticals' gross revenue, earnings per share and valuation.

Aeolus Pharmaceuticals has lower revenue, but higher earnings than Akorn.

Institutional and Insider Ownership

0.1% of Akorn shares are owned by institutional investors. 3.9% of Akorn shares are owned by insiders. Comparatively, 66.6% of Aeolus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Akorn and Aeolus Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent ratings for Akorn and Aeolus Pharmaceuticals, as provided by MarketBeat.

Volatility and Risk

Akorn has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500. Comparatively, Aeolus Pharmaceuticals has a beta of 2.38, meaning that its share price is 138% more volatile than the S&P 500.

Summary

Aeolus Pharmaceuticals beats Akorn on 5 of the 7 factors compared between the two stocks.

VG Life Sciences (OTCMKTS:VGLS) and Aeolus Pharmaceuticals (OTCMKTS:AOLS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent ratings for VG Life Sciences and Aeolus Pharmaceuticals, as provided by MarketBeat.

Volatility and Risk

VG Life Sciences has a beta of 1.61, indicating that its share price is 61% more volatile than the S&P 500. Comparatively, Aeolus Pharmaceuticals has a beta of 2.38, indicating that its share price is 138% more volatile than the S&P 500.

Profitability

This table compares VG Life Sciences and Aeolus Pharmaceuticals' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares VG Life Sciences and Aeolus Pharmaceuticals' gross revenue, earnings per share and valuation.

Summary

Aeolus Pharmaceuticals beats VG Life Sciences on 1 of the 1 factors compared between the two stocks.

RespireRx Pharmaceuticals (OTCMKTS:RSPI) and Aeolus Pharmaceuticals (OTCMKTS:AOLS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, risk, earnings, profitability, valuation, dividends and institutional ownership.

Volatility and Risk

RespireRx Pharmaceuticals has a beta of 0.43, meaning that its share price is 57% less volatile than the S&P 500. Comparatively, Aeolus Pharmaceuticals has a beta of 2.38, meaning that its share price is 138% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and target prices for RespireRx Pharmaceuticals and Aeolus Pharmaceuticals, as provided by MarketBeat.

Profitability

This table compares RespireRx Pharmaceuticals and Aeolus Pharmaceuticals' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares RespireRx Pharmaceuticals and Aeolus Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Summary

Aeolus Pharmaceuticals beats RespireRx Pharmaceuticals on 2 of the 2 factors compared between the two stocks.

Aeolus Pharmaceuticals (OTCMKTS:AOLS) and Immune Pharmaceuticals (OTCMKTS:IMNPQ) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability.

Risk and Volatility

Aeolus Pharmaceuticals has a beta of 2.38, meaning that its stock price is 138% more volatile than the S&P 500. Comparatively, Immune Pharmaceuticals has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Aeolus Pharmaceuticals and Immune Pharmaceuticals, as reported by MarketBeat.

Profitability

This table compares Aeolus Pharmaceuticals and Immune Pharmaceuticals' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Aeolus Pharmaceuticals and Immune Pharmaceuticals' gross revenue, earnings per share and valuation.

Summary

Aeolus Pharmaceuticals beats Immune Pharmaceuticals on 1 of the 1 factors compared between the two stocks.

Aeolus Pharmaceuticals (OTCMKTS:AOLS) and Innovus Pharmaceuticals (OTCMKTS:INNVD) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability.

Risk and Volatility

Aeolus Pharmaceuticals has a beta of 2.38, meaning that its stock price is 138% more volatile than the S&P 500. Comparatively, Innovus Pharmaceuticals has a beta of 2.89, meaning that its stock price is 189% more volatile than the S&P 500.

Profitability

This table compares Aeolus Pharmaceuticals and Innovus Pharmaceuticals' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Aeolus Pharmaceuticals and Innovus Pharmaceuticals' gross revenue, earnings per share and valuation.

Aeolus Pharmaceuticals has higher earnings, but lower revenue than Innovus Pharmaceuticals.

Analyst Ratings

This is a breakdown of recent recommendations for Aeolus Pharmaceuticals and Innovus Pharmaceuticals, as reported by MarketBeat.

Insider and Institutional Ownership

10.4% of Innovus Pharmaceuticals shares are held by institutional investors. 66.6% of Aeolus Pharmaceuticals shares are held by insiders. Comparatively, 16.4% of Innovus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Aeolus Pharmaceuticals beats Innovus Pharmaceuticals on 4 of the 7 factors compared between the two stocks.

Aeolus Pharmaceuticals (OTCMKTS:AOLS) and Inspyr Therapeutics (OTCMKTS:NSPX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, dividends, profitability and risk.

Earnings & Valuation

This table compares Aeolus Pharmaceuticals and Inspyr Therapeutics' revenue, earnings per share (EPS) and valuation.

Profitability

This table compares Aeolus Pharmaceuticals and Inspyr Therapeutics' net margins, return on equity and return on assets.

Risk & Volatility

Aeolus Pharmaceuticals has a beta of 2.38, meaning that its stock price is 138% more volatile than the S&P 500. Comparatively, Inspyr Therapeutics has a beta of -16.55, meaning that its stock price is 1,755% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings for Aeolus Pharmaceuticals and Inspyr Therapeutics, as reported by MarketBeat.

Summary

Aeolus Pharmaceuticals beats Inspyr Therapeutics on 2 of the 2 factors compared between the two stocks.